Jun 11, 2020 / 06:10PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Moderna with us today. And with us is Stéphane Bancel, CEO of the company.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPSo Stéphane, to start here, just given the COVID-19 pandemic, Moderna has the opportunity here to demonstrate the potential of the mRNA platform as it relates to vaccine development over the course of a few months versus what would have typically taken 2 to 5 years or maybe even more. Why is Moderna positioned to successfully develop a vaccine and supply it to the global population?
Stéphane Bancel - Moderna, Inc. - CEO & Director
Yes. So Salveen, good afternoon, and thank you for having us. I think a few reasons. I mean first, we believed since we started the company, that mRNA could be potentially the best
Trustpilot
